| Nov 18 |
Alnylam releases encouraging interim data on nucresiran for ATTR amyloidosis
|
| Nov 18 |
ALNY Reports Sustained 6-Month Efficacy Data From Amyloidosis Study
|
| Nov 18 |
Alnylam reveals trial outcomes of nucresiran for ATTR amyloidosis treatment
|
| Nov 17 |
Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose
|
| Nov 12 |
Alnylam downgraded at Wolfe on doubts over Amvuttra growth
|
| Nov 12 |
3 US Stocks Estimated To Be Trading At Discounts Up To 48.8%
|
| Nov 6 |
Top 20 biopharmas’ market cap rises 2% in Q3 2024 amid flurry of drug approvals
|
| Nov 6 |
An RNAi renaissance is creating a new generation of startups
|
| Nov 4 |
Alnylam to Webcast Presentations at Upcoming November Investor Conferences
|
| Nov 1 |
Alnylam Q3 Loss In Line With Estimates, Revenues Miss, Stock Down
|
